[1] 张杰,王晓娜,肖文凯,等. 高龄动脉粥样硬化性心血管疾病患者他汀疗效分析[J]. 解放军医学院学报,2020,41(5):440-445.
[2] 北京高血压防治协会,北京糖尿病防治协会,北京慢性病防治与健康教育研究会,等. 基层心血管病综合管理实践指南2020[J]. 中国医学前沿杂志(电子版),2020,12(8):前插1,1-73.
[3] 张业腾,秦玲. 他汀类药物治疗ASCVD的现状及展望[J]. 临床医药文献电子杂志,2019,6(67) :176-177.
[4] 张凌,江涛,赖艳辉.人类SLCO1B1和ApoE基因在脂代谢异常患者药物治疗中的检测意义分析[J]. 当代医学,2020,26(9):7-9.
[5] 刘艳辉,董婧,陆燕,等. SLCO1B1521 T>C和APOE基因多态性对阿托伐他汀调脂疗效及安全性的影响[J]. 药学实践杂志,2021,39(3):245-248.
[6] 中国心血管健康与疾病报告2020[J]. 心肺血管病杂志,2021,40(9):885-889.
[7] 中国成人血脂异常防治指南修订联合委员会. 中国成人血脂异常防治指南(2016年修订版)[J]. 中华全科医师杂志,2017,16(1):15-35.
[8] Stone NJ, Robinson JG, Lichtenstein AH, et al.2013 ACC/AHA juideline on the treatment of blood cholesteron to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology /American Heat Association Task Force on Practice Guidelines[J].J Am Coll Cardiol,2014,63(25PtB):2889-2934.
[9] Jacobson TA, Ito MK, Maki KC, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1: full report[J]. J Clin Lipidol,2015,9(2):129-169.
[10] Guan ZW, Wu KR, Li R, et al. Pharmacogenetics of statins treatment: efficacy and safety[J]. J Clin Pharm Ther, 2019,44(6):858-867.
[11] Meyer zu Schwabedissen HE, Albers M, Baumeister SE,et al. Function-impairing polymorphisms of the hepatic uptake transporter SLCO1B1 modify the therapeutic efficacy of statins in a population-based cohort[J]. Pharmacogenet Genomics, 2015, 25(1):8-18.
[12] 边素艳,王艳丽,刘宏斌. 动脉粥样硬化性心血管病危险分层患者SLCO1B1和载脂蛋白E基因多态性与血脂的关系[J]. 中华老年心脑血管病杂志,2018,20(7):676-680.
[13] 白颖,史旭波,王建旗,等. SLCO1B1 521T>C和388A>G基因多态性对冠心病患者阿托伐他汀降脂疗效的影响[J]. 中国药物应用与监测,2021,18(3):143-146.
[14] Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms[J]. Clin Pharmacol Ther, 2022,111(5):1007-1021.
[15] 席宁,王永辉,周静,等. ApoE基因多态性对缺血性脑梗死患者他汀类降脂药物治疗效果的影响[J]. 中华医学遗传学杂志,2022,39(1):94-98.
[16] Kirac D, Bayam E, Dagdelen M, et al. HMGCR and ApoE mutations may cause different responses to lipid lowering statin therapy[J]. Cell Mol Biol (Noisy-le-grand),2017,63(10):43-48. |
